Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
Human brain organoids flourish in emptied mouse cortex
The chimeric mice could help untangle the biology of human brain development or conditions such as autism.
Human brain organoids flourish in emptied mouse cortex
The chimeric mice could help untangle the biology of human brain development or conditions such as autism.
What if Hegel were a neuroscientist?
Andrea Gambarotto shares what Hegel and enactivism have in common: an agency-first approach to understanding minds and brains.
What if Hegel were a neuroscientist?
Andrea Gambarotto shares what Hegel and enactivism have in common: an agency-first approach to understanding minds and brains.